{"entity":{"id":"keros-therapeutics","kind":"company","name":"Keros Therapeutics","aka":["Keros Therapeutics, Inc.","NASDAQ:KROS"],"tldr":"Keros Therapeutics is a Massachusetts biotech that works on the TGF-beta family signals controlling blood cell production; its activin ligand trap elritercept treats anaemia in myelodysplastic syndromes and myelofibrosis and was licensed to Takeda.","summary":"Keros Therapeutics develops medicines that modulate transforming growth factor beta superfamily signalling. Elritercept (KER-050, now TAK-226) is a modified activin receptor type IIA ligand trap that promotes red cell and platelet production; it showed durable transfusion independence in lower-risk myelodysplastic syndromes and myelofibrosis and was licensed to Takeda outside mainland China in December 2024. Cibotercept (KER-012) was studied in pulmonary arterial hypertension and KER-065 is in development for neuromuscular disease.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.kerostx.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["elritercept"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Lexington, Massachusetts","country":"US","companyType":"biotech","website":"https://www.kerostx.com/","ticker":"NASDAQ:KROS","founded":2015,"stage":"public","investors":[],"funding":[]},"route":"/companies/keros-therapeutics/","neighbours":{"drug":[{"id":"elritercept","kind":"drug","name":"Elritercept","route":"/drugs/elritercept/"}]}}